Repligen (RGEN) Cash from Financing Activities (2010 - 2026)
Repligen (RGEN) reported Cash from Financing Activities of -$5.5 million for Q1 2026, down 10.2% year-over-year from -$6.2 million in Q1 2025, and down 2942.56% quarter-over-quarter from $195000.0 in Q4 2025.
Repligen (RGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Repligen (RGEN) has 17 years of Cash from Financing Activities data on file, last reported at -$5.5 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$5.5 million, down 10.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.7 million (up 80.09% YoY), and the FY2025 annual result was -$15.2 million, up 81.66% from the prior year.
- Cash from Financing Activities declined to -$5.5 million in Q1 2026 per RGEN's latest filing, from $195000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $268.1 million in Q4 2023 and troughed at -$69.6 million in Q3 2024.
- A 5-year average of $7.8 million and a median of -$5.0 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 97956.57% in 2023, then slumped 8846.53% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$274000.0 in 2022, then surged by 97956.57% to $268.1 million in 2023, then tumbled by 99.46% to $1.4 million in 2024, then sank by 86.54% to $195000.0 in 2025, then slumped by 2942.56% to -$5.5 million in 2026.
- Business Quant data shows RGEN's Cash from Financing Activities at -$5.5 million in Q1 2026, $195000.0 in Q4 2025, and -$239000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Repligen | 7.41 Bn | 6.42 Bn | 108.28 Mn | -5.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Jun 30, 2025 | -10.13 Mn |
| Jun 30, 2025 | -10.13 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | -69.60 Mn |
| Sep 30, 2024 | -69.60 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -8.97 Mn |
| Mar 31, 2024 | -8.97 Mn |
| Dec 31, 2023 | 268.13 Mn |
| Dec 31, 2023 | 268.13 Mn |